Análisis Argos
NOVT
NOVTCara
Novanta Inc. · Technology
US$ 161.72
precio al 2026-07-04
Valor justo Argos*
US$ 91
vs. su valor justo
−44%
Score Argos
32/100
LA RESPUESTA
El mercado le pide crezca 53.4% al año — más de lo que ha demostrado (7%). Estás pagando un futuro que todavía no probó: el margen de error es mínimo.
Recompensas
Tiene más caja que deuda: balance fuerte.
Riesgos
!El precio pide más crecimiento del que la empresa ha demostrado.
!Venta significativa de insiders en el último trimestre.
VALOR1/6FUTURO3/6PASADO2/6SALUD4/6DIVIDENDO2/6
El Iris de calidad
VALOR1/6FUTURO3/6PASADO2/6SALUD4/6DIVIDENDO2/6
ValorCotiza por encima de su valor justo
FuturoCrecimiento moderado
PasadoHistorial aceptable
SaludBalance fuerte, deuda controlada
DividendoRetorno al accionista moderado
Score Argos32de 100Cara
Ingresos3%
US$ 1 B
Margen operativo3%
11.9%
Flujo de caja libre64%
US$ 0.1 B
Deuda neta
US$ -0 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 5.8B
P/E107x
EV/EBITDA32x
FCF yield0.8%
ROIC7.1%
Margen operativo11.9%
Crecim. ingresos+3.3%/año
Piotroski F5/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

zacks.com · 25 jun
Novanta (NOVT) Upgraded to Buy: What Does It Mean for the Stock?
Novanta (NOVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
businesswire.com · 22 jun
Novanta to Present at the CJS Securities 26th Annual New Ideas Summer Conference on Thursday, July 9, 2026
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, and Chuck Ravetto, Chief Operating Officer, are scheduled to present at the CJS Securities 26th Annual New Ideas Summer Conference on Thursday, July 9, 2026, in White Plains, NY. About Novanta Novanta is a leading global supplier of core technology solutions that give medical,.
zacks.com · 17 jun
Novanta (NOVT) is a Great Momentum Stock: Should You Buy?
Does Novanta (NOVT) have what it takes to be a top stock pick for momentum investors? Let's find out.
seekingalpha.com · 10 jun
Novanta Inc. (NOVT) M&A Call Transcript
Novanta Inc. (NOVT) M&A Call Transcript
businesswire.com · 9 jun
Novanta Inc. Announces $300 Million Private Placement
BOSTON--(BUSINESS WIRE)--Novanta Inc. ("Novanta" or the “Company”) announced today that it has entered into a securities purchase agreement for a private placement of the Company's common shares (“Common Shares”) to institutional and other accredited investors that is expected to result in gross proceeds of approximately $300 million to the Company, before placement agent fees and offering expenses. Pursuant to the terms of the securities purchase agreement, the investors agreed to purchase an.
businesswire.com · 9 jun
Novanta Inc. Announces Acquisition of Riverpoint Medical
BOSTON--(BUSINESS WIRE)--Novanta Inc. (NASDAQ: NOVT) (“Novanta” or the “Company”), a trusted technology partner to leading global medical and industrial original equipment manufacturers (OEMs), today announced that it has entered into a definitive agreement to acquire Riverpoint Medical (“Riverpoint Medical” or “Riverpoint”), a category leader in high-growth minimally invasive surgical consumables, from Arlington Capital Partners (“Arlington”), a Washington D.C.-area private investment firm. Un.
gurufocus.com · 8 jun
A Look at Novanta Inc (NOVT) After 5.1% Gain -- GF Value $153.89 vs Price $164.34
On June 08, 2026, Novanta Inc (NOVT) shares rose 5.1% to $164.34. This increase comes amid a strong year-to-date performance, with shares up 38.1%, and a signif
gurufocus.com · 22 may
A Look at Novanta Inc (NOVT) After 3.1% Gain -- GF Value $154.22 vs Price $159.70
On May 22, 2026, Novanta Inc (NOVT) shares rose 3.1% to $159.70, reflecting a positive price movement amid a strong performance over the past month and year. Th

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.